Glyphic Biotechnologies

About:

Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform.

Twitter/X: GlyphicBio

Top Investors: National Institutes of Health, Wing Venture Capital, Qiagen, OUP (Osage University Partners), Cantos

Description:

Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.

Total Funding Amount:

$7.78M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2021-01-01

Contact Email:

letschat(AT)glyphic.bio

Founders:

Daniel Estandian, Joshua Yang

Number of Employees:

11-50

Last Funding Date:

2024-01-25

IPO Status:

Private

Industries: